Moderna COVID-19 Vaccine (Spikevax)

概览

Moderna COVID-19 Vaccine is an mRNA vaccine for the prevention of COVID-19, the disease caused by the SARS-CoV-2 virus, in patients aged 18 years and older.

作用机制

The Moderna COVID-19 Vaccine is a vaccine that contains synthetic nucleoside-modified messenger RNA (mRNA) encapsulated in Lipid nanoparticle (LNP) which codes for the full-length, pre-fusion stabilized spike protein (S) of SARS-CoV-2. The S glycoprotein is a large transmembrane protein that plays a critical role in viral attachment, fusion, and entry into the host cell. Upon vaccination, human cells express the SARS-CoV-2 S antigen and immune response to the S antigen is elicited, leading to the protection against SARS-CoV-2.

适应症

The Moderna COVID-19 Vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older in the US and Europe, and in individuals 6 months of age and older in Canada. In the US, under the emergency use authorization, the Moderna COVID-19 Vaccine is used for the prevention of COVID-19 in children 6 months of age and older.[L42770] It is administered in two doses, one month (28 days) apart. A booster dose of the vaccine, to be given at least 6 months following the initial vaccine series, is approved for use in all patients 18 years of age and older in Canada and the US. The Moderna COVID-19 vaccine is also approved for use as a fourth booster shot in adults 50 years of age and older. A bivalent formulation of the Moderna vaccine which includes davesomeran - targeting the BA.4 and BA.5 Omicron variants - was approved in August 2022 by the FDA and in November 2022 by Health Canada. In Canada, an additional bivalent formulation which includes imelasomeran - targeting the BA.1 Omicron variant - was approved in September 2022, and may be used as a booster dose in individuals ≥6 years of age.

• Coronavirus Disease 2019 (COVID‑19)